falsefalse

The Evolving Treatment Paradigm for Stage I-IIIA NSCLC - Episode 11

Exciting NSCLC Data Updates from ESMO 2022

, , , ,

The panel shares the data that excited them the most from ESMO 2022, and what to look forward to in the future.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Recommendations for Molecular Testing in Non-Small Cell Lung Cancer (NSCLC)
    EP. 2: Molecular Testing in Early NSCLC to Guide Treatment Decision Making
    EP. 3: Is There a Role for Liquid Biopsies in Early NSCLC?
    EP. 4: Updates in the Treatment of Stage I-IIIA NSCLC
    EP. 5: The Role of Neoadjuvant Therapy in Patients with Resectable NSCLC
    EP. 6: Selecting Appropriate Patients with NSCLC for Neoadjuvant Therapy
    EP. 7: The Role of Adjuvant Therapy in Patients with NSCLC
    EP. 8: Updates on Adjuvant Osimertinib for NSCLC Treatment from the ADUARA Trial
    EP. 9: Adjuvant Therapy in EGFR-Mutated NSCLC
    EP. 10: NSCLC Molecular Testing Recommendations for Community Hospitals
    Now Viewing
    EP. 11: Exciting NSCLC Data Updates from ESMO 2022

    Related Content:

    The Evolving Treatment Paradigm for Stage I-IIIA NSCLCLung CancerOncLive Peer Exchange®
    Adjuvant Aumolertinib Boosts DFS in Stage II-IIIB, EGFR-Mutated NSCLC
    Adagrasib Yields Early Efficacy in STK11- and KRAS G12C–Mutant NSCLC
    Lung Cancer Experts Highlight the Significance and Limitations of ADCs
    x